Gain of 1q21 and distinct adverse cytogenetic abnormalities correlate with increased microcirculation in multiple myeloma

被引:16
作者
Hillengass, Jens [1 ]
Zechmann, Christian M. [2 ]
Nadler, Andreas [1 ]
Hose, Dirk
Cremer, Friedrich W. [3 ]
Jauch, Anna [3 ]
Heiss, Christiane [4 ,5 ]
Benner, Axel [4 ]
Ho, Anthony D. [1 ]
Bartram, Claus R.
Kauczor, Hans-Ulrich [2 ]
Delorme, Stefan [2 ]
Goldschmidt, Hartmut [1 ,5 ]
Moehler, Thomas M. [1 ]
机构
[1] Univ Heidelberg, Dept Hematol Oncol & Rheumatol, D-69120 Heidelberg, Germany
[2] German Canc Res Ctr, Dept Radiol, D-6900 Heidelberg, Germany
[3] Univ Heidelberg, Inst Human Genet, D-69120 Heidelberg, Germany
[4] German Canc Res Ctr, Dept Biostat, D-6900 Heidelberg, Germany
[5] Natl Ctr Tumor Dis, Sect Multiple Myeloma, Heidelberg, Germany
关键词
multiple myeloma; monoclonal gammopathy of undetermined significance; dynamic contrast-enhanced magnetic resonance imaging; cytogenetics; in situ fluorescence hybridization;
D O I
10.1002/ijc.23455
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
To identify genetic mechanisms controlling bone marrow microcirculation and angiogenesis in patients with plasma cell disease we simultaneously performed bone marrow dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) and cytogenetics (iFISH) on CD138 purified plasma cells of MGUS (n = 31) and untreated multiple myeloma (MM) (n = 87) patients. The adverse cytogenetic abnormalities gain of 1q21, deletion 17p13 and deletion 13q14 significantly correlated with at least one DCE-MRI finding (aberrant "focal" microcirculation pattern, increase in median microcirculation parameter Amplitude A or exchange rate constant kep). We conclude that gain of 1q21, deletion 13q14 and deletion 17p13 trigger the angiogenic cascade in MM. Our findings will have important implications for the design, analysis and stratification for clinical studies of patients with MM in particular if compounds with antiangiogenic activity are used. (C) 2008 Wiley-Liss, Inc.
引用
收藏
页码:2871 / 2875
页数:5
相关论文
共 50 条
  • [1] Prognostic Value of 1q21 Gain in Multiple Myeloma
    Chen, Dangui
    Zhou, Di
    Xu, Jingyan
    Zhou, Rongfu
    Ouyang, Jian
    Chen, Bing
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 (03) : E159 - E164
  • [2] Predictive value of 1q21 gain in multiple myeloma is strongly dependent on concurrent cytogenetic abnormalities and first-line treatment
    Minguela, Alfredo
    Vasco-Mogorron, Maria A.
    Campillo, Jose A.
    Cabanas, Valentin
    Remigia, Maria J.
    Berenguer, Mercedes
    Garcia-Garay, Maria C.
    Blanquer, Miguel
    Cava, Catalina
    Galian, Jose Antonio
    Gimeno, Lourdes
    Soto-Ramirez, Maria F.
    Martinez-Hernandez, Maria D.
    de la Rubia, Javier
    Teruel, Ana, I
    Muro, Manuel
    Periago, Adela
    AMERICAN JOURNAL OF CANCER RESEARCH, 2021, 11 (09): : 4438 - +
  • [3] Gain/Amplification of Chromosome Arm 1q21 in Multiple Myeloma
    Hanamura, Ichiro
    CANCERS, 2021, 13 (02) : 1 - 16
  • [4] The independent adverse prognostic significance of 1q21 gain/amplification in newly diagnosed multiple myeloma patients
    You, Hongying
    Jin, Song
    Wu, Chunxiao
    Wang, Qingqing
    Yan, Shuang
    Yao, Weiqin
    Shi, Xiaolan
    Shang, Jingjing
    Yan, Lingzhi
    Yao, Ying
    Wang, Jing
    Wang, Panfeng
    Pan, Jinlan
    Wu, Depei
    Fu, Chengcheng
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [5] Prognostic value of 1q21 amplification in multiple myeloma
    Abramova, T. V.
    Obukhova, T. N.
    Mendeleev, L. P.
    Pokrovskaya, O. S.
    Gribanova, E. O.
    Ryzhko, V. V.
    Grebenyuk, L. A.
    Nareyko, M. V.
    Solovyev, M. V.
    Votyakova, O. M.
    Kulikov, S. M.
    Rusinov, M. A.
    Savchenko, V. G.
    TERAPEVTICHESKII ARKHIV, 2017, 89 (07) : 32 - +
  • [6] Gain of 1q21 is an adverse prognostic factor for multiple myeloma patients treated by autologous stem cell transplantation: A multicenter study in China
    Gao, Wen
    Jian, Yuan
    Du, Juan
    Li, Xiaozhe
    Zhou, Huixing
    Zhang, Zhiyao
    Yang, Guangzhong
    Wang, Guorong
    Tian, Ying
    Li, Yanchen
    Wu, Yin
    Fu, Weijun
    Li, Juan
    Chen, Wenming
    CANCER MEDICINE, 2020, 9 (21): : 7819 - 7829
  • [7] The amplification of 1q21 is an adverse prognostic factor in patients with multiple myeloma in a Chinese population
    Yu, Wenjun
    Guo, Rui
    Qu, Xiaoyan
    Qiu, Hairong
    Li, Jianyong
    Zhang, Run
    Chen, Lijuan
    ONCOTARGETS AND THERAPY, 2016, 9 : 295 - 301
  • [8] Amp 1q21 is more predictable with dismal survival than gain 1q21 of newly diagnosed multiple myeloma in real-world analysis
    Wang, Yu-Tong
    Bao, Li
    Chu, Bin
    Chen, Xiao-Huan
    Lu, Min-Qiu
    Shi, Lei
    Gao, Shan
    Fang, Li-Juan
    Xiang, Qiu-Qing
    Ding, Yue-Hua
    JOURNAL OF CLINICAL LABORATORY ANALYSIS, 2022, 36 (07)
  • [9] Chromosomal 1q21 abnormalities in multiple myeloma: a review of translational, clinical research, and therapeutic strategies
    Bisht, Kamlesh
    Walker, Brian
    Kumar, Shaji K.
    Spicka, Ivan
    Moreau, Philippe
    Martin, Tom
    Costa, Luciano J.
    Richter, Joshua
    Fukao, Taro
    Mace, Sandrine
    van de Velde, Helgi
    EXPERT REVIEW OF HEMATOLOGY, 2021, 14 (12) : 1099 - 1114
  • [10] The prognostic role of 1q21 gain/amplification in newly diagnosed multiple myeloma: The faster, the worse
    Wang, Yawen
    Xu, Jiadai
    Xu, Bei
    Li, Panpan
    Yang, Yang
    Wang, Wenjing
    Xu, Tianhong
    Maihemaiti, Aziguli
    Lan, Tianwei
    Wang, Pu
    Ren, Liang
    Zhou, Chi
    Aihemaiti, Xianmuseye
    Liu, Peng
    CANCER, 2023, 129 (07) : 1005 - 1016